Recombinant Human BAFF/TNFSF13B protein (hFc Tag)
ED50
0.6-2.4 ng/mL
Species
Human
Purity
>90 %, SDS-PAGE
GeneID
10673
Accession
Q9Y275-1
验证数据展示
Technical Specifications
Purity | >90 %, SDS-PAGE |
Endotoxin Level | <1.0 EU/μg protein, LAL method |
Biological Activity |
Immobilized Human BCMA (Myc tag, His tag) at 2 μg/mL (100 μL/well) can bind Human BAFF (hFc tag) with a linear range of 0.6-2.4 ng/mL. |
Source | HEK293-derived Human BAFF protein Ala134-Leu285 (Accession# Q9Y275-1) with a human IgG1 Fc tag at the N-terminus. |
Predicted Molecular Mass | 43 kDa |
SDS-PAGE | 45-50 kDa, reducing (R) conditions |
Formulation | Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
Storage |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
TNFSF13B, also known as BAFF, BLYS, TALL1, TNFSF20, ZTNF4 and CD257, is a cytokine that binds to TNFRSF13B/TACI and TNFRSF17/BCMA. This cytokine is expressed in B lineage cells, and acts as a potent B cell activator. The BAFF system promotes B cell survival and differentiation and plays a prominent role in the pathogenesis of autoimmune diseases. It has been shown that BAFF inhibitors are in clinical trials for systemic lupus erythematosus with significant efficacy.
References:
1. Cristian R Smulski et al (2018). Front Immunol. Oct 8;9:2285. 2. Edina Schweighoffer et al (2021). Curr Opin Immunol. Aug;71:124-131. 3. Anne Davidson. (2010). Curr Opin Immunol. Dec;22(6):732-9. 4. Shingo Nakayamada et al (2016).Inflamm Regen. Jul 21;36:6.